Purpose: Increased levels of antiphosholipid antibodies (aPLs) are associated with the autoimmune disorder antiphospholipid syndrome (APS) and are known to play a role in infertility. We investigated the possible effect of prolonged use of hormonal contraception (HC) on autoimmunity after discontinuing HC in women with infertility problems. Material and Methods: We analyzed hormonal status including ovulation and the humoral autoimmune response to eight phospholipids detected by ELISA in 1190 infertile women aged 21-46 (mean age: 29.3) years. Results: Long-term HC did not affect ovulation, but in the absence of ovulation HC masked the hormonal disorders. The majority of patients taking HC for more than 10 years with fertility failure had significantly higher levels of aPLs of the IgG isotype against phosphatidylinositol and phosphatidylserine (p > 0.001) than against β2-glycoprotein I and annexin V. Discussion: Thus, high levels of aPLs are significant for the anticoagulant treatment before and during pregnancy to prevent pregnancy loss.

Zielsetzung: Das erhöhte Auftreten von Antiphospholipid-Antikörpern im Blut ist mit der Autoimmunerkrankung Antiphospholipid-Syndrom (APS) assoziiert und spielt bekanntlich eine Rolle bei Infertilität. In Frauen mit Fertilitätsproblemen wurde die mögliche Auswirkung der Langzeiteinnahme hormoneller Empfängnisverhütungsmittel auf die Autoimmunität untersucht, die auch nach Absetzen des Mittels fortbesteht. Methoden: In 1190 unfruchtbaren Frauen im Alter von 21–46 (Durchschnittsalter: 29,3) Jahren wurden Hormonstatus und Eisprung sowie die durch ELISA ermittelte humorale Immunreaktion auf 8 Phospholipide untersucht. Ergebnisse: Die Langzeiteinnahme hormoneller Empfängnisverhütungsmittel hatte keine Auswirkung auf den Eisprung, aber bei Ausbleiben des Eisprungs hat die hormonelle Empfängnisverhütung die Hormonstörung überdeckt. Die Mehrheit der Patientinnen mit Fertilitätsproblemen, die Hormonpräparate zur Empfängnisverhütung über einen Zeitraum von mehr als 10 Jahren einnahmen, wiesen signifikant höhere Antiphospholipid-Antikörper-Spiegel des IgG-Isotyps gegen Phosphatidylinositol und Phosphatidylserin (p > 0,001) auf als gegen β2-Glykoprotein I und Annexin V. Diskussion: Hohe Antiphospholipid-Antikörper-Spiegel erweisen sich also als signifikant für die antikoagulatorische Therapie vor und während der Schwangerschaft, um einem frühzeitigen Ende der Schwangerschaft vorzubeugen.

Dept Gynecology Obstetrics Charles University Pilsen Czech Republic

Genetics Pilsen Pilsen Czech Republic

Genetics Pilsen Pilsen Czech Republic ; Dept Gynecology Obstetrics Charles University Pilsen Czech Republic

Zobrazit více v PubMed

Cameron S T, Glasier A. London: Wiley-Blackwell; 2012. Chapter 40; pp. 495–512.

Sulak P J, Scow R D, Preece C. et al.Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–266. PubMed

Müller-Jahncke W D. [Ludwig Haberlandt (1885–1932) and the development of hormonal contraception] Z Gesamte Inn Med. 1988;43:420–422. PubMed

Perone N. The history of steroidal contraceptive development: the progestins. Perspect Biol Med. 1993;36:347–362. PubMed

Wasserman A. Über die Entwicklung und den gegenwärtigen Stand der Serodiagnostik gegenüber Syphilis. Berlin: Klin Wochenschr. 1907;44:1599–1605.

Pangborn M C. A new serologically active phospholipids from beef heart. Proc Soc Exp Biol Med. 1941;48:484–486.

Cervera R, Piette J C, Font J. et al.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthr Rheumat. 2002;46:1019–1027. PubMed

Ruffatti A, Del Ross T, Ciprian M. et al.Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083–1086. PubMed

Shoenfeld Y, Blank M. Autoantibodies associated with reproductive failure. Lupus. 2004;9:643–648. PubMed

Roubey R A. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996;39:1444–1454. PubMed

Gleicher N, El-Roeity A, Confino E. et al.Reproductive failure because of autoantibodies unexplained infertility and pregnancy wastage. Am J Obstet Gynecol. 1989;160:1376–1380. PubMed

Chaouat G. Regulation of cellular immune response from the mother to the paternal antigens of the conceptus. Prog Clin Biol Res. 1981;70:137–144. PubMed

Hemberger M. Immune balance at the foeto-maternal interface as the fulcrum of reproductive success. J Reprod Immunol. 2013;97:36–42. PubMed

McNeil H P, Chesterman C N, Krilis S A. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 1991;49:193–280. PubMed

Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. Human Reprod Update. 2008;14:359–366. PubMed

Carp J A, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun. 2012;38:266–274. PubMed

Ulcova-Gallova Z. Repeated miscarriages in patients with antiphospholipid syndrome and subjected to in vitro fertilization: the importance of preimplantation genetic diagnosis. Lupus. 2012;21:744–746. PubMed

Ulcova-Gallova Z, Krauz V, Novakova P. et al.Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Am J Reprod Immunol. 2005;54:112–117. PubMed

Ulcova-Gallova Z, Mukensnabl P, Hadravska S. et al.Antibodies against annexin V and prothrombin, their correlation with other anti-phospholipid antibodies in recurrent pregnancy loss. J Reprod Contraception. 2005;16:35–46.

Tincani A, Spatola M, Cinquioni M. et al.Animal models of antiphospholipid syndrome. Rev Rheumat. 1998;65:614–618. PubMed

World Health Organization . Geneva, Switzerland: WHO Press; 2010. WHO Laboratory Manual for the Examination and Processing of human Semen. 5th ed; pp. 1–286.

Mackworth-Young C G. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol. 2004;136:393–401. PubMed PMC

Buyon J P, Petri M A, Kim M Y. et al.The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953–962. PubMed

Girolami A, Zanon E, Zanardi S. et al.Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 1996;7:497–501. PubMed

Julkunen H, Kaaja R, Jouhikainen T. et al.Malignant hypertension and antiphospholipid antibodies as presenting features of SLE in a young woman using oral contraceptives. Br J Rheumatol. 1991;30:471–482. PubMed

Duarte C, Inês L. Oral contraceptives and systemic lupus erythematosus: what should we advise to our patients. Acta Reumatol. 2010;35:133–140. PubMed

Lakasing L, Khamashta M J. Contraceptive practices in women with systemic lupus erythematosus and/or antiphospholipid syndrome: what advice should we be giving? Fam Plann Reprod Health Care. 2001;27:7–12. PubMed

Yazdany J, Trupin L, Kaiser R. et al.Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality? Arthr Care Res. 2011;63:358–365. PubMed PMC

Lateef A, Petri M. Hormone replacement and contraceptive therapy in autoimmune disease. J Autoimmun. 2012;38:J170–J176. PubMed

Bernier M O, Mikaetoff Y, Hudson M. et al.Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthr Rheumat. 2009;61:476–481. PubMed

Devreese K M. Antiphospholipid antibody testing and standardization. Int J Lab Hematol. 2014;36:352–363. PubMed

Globerson A, Effros R B. Ageing of lymphocytes and lymphocytes in the aged. Immunol Today. 2000;21:515–521. PubMed

Hradecky L, Subrt I, Ulcova-Gallova Z. Urgent termination of pregnancy in pre-eclampsia and panel of antiphospholipid antibodies. Am J Reprod Immunol. 2009;62:412–417. PubMed

Kwak-Kim J, Agcaoili M S, Aleta L. et al.Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol. 2013;69:596–607. PubMed